Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.-MedSci.cn

Phase 1 study to determine the safety and efficacy of onvansertib, a novel, oral, PLK1 inhibitor in patients with proliferative chronic myelomonocytic leukemia relapsed/refractory or intolerant to available therapies.

McCullough, K; Mangaonkar, AA; Burgess, AR; Al-Kali, A; Alkhateeb, HB; Begna, K; Gangat, N; Geyer, SM; Hogan, WJ; Litzow, MR; Reichard, K; Saliba, AN; Shah, MV; Wolanskyj-Spinner, AP; Patnaik, MM

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务